Home /

Identification of a high-risk subgroup in primary prostate cancers presenting with targetable immune biology

Integrative clustering of multi-omics data revealed 2 subgroups of patients with metastatic-like biology that have distinct biology. 17% of the patients show greater genomic instability and present with targetable immune biology –that can be identified with the combination of the DDRD and PCM assays. This subgroup can be reproduced with the expression of 8q genes alone. The group is also identified in an independent data set and represents 14% of the n=321 cohort. The Metastatic-like DDRD group is shown to be at increased risk of biochemical recurrence & metastatic disease. It may represent a viable target population for immune checkpoint and DNA damaging treatment.

View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies